
Pharma Business - July 7, 2025
AstraZeneca’s Imfinzi approved in the EU
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).

Collaboration - June 13, 2025
Salipro Biotech enters collaboration agreement with Daewoong Pharmaceutical
The collaboration combines Salipro Biotech's expertise and its Salipro platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs.

Agreement - June 12, 2025
Key2Brain enters worldwide licensing agreement with Chiesi Group
The two companies will advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system.

CDMO - June 9, 2025
ReciBioPharm expand collaboration with University of Oxford
The University of Oxford and ReciBioPharm, Recipharm’s Advanced Biologics division are expanding their collaboration with the development of two blood-stage malaria vaccine candidates for Phase 1/2 clinical trials.

Pharma Business - May 30, 2025
AstraZeneca’s Imfinzi recommended for approval in the EU
Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).

Agreement - May 27, 2025
Orion announces agreement with Shilpa Medicare
Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited, have entered into an agreement to commercialize Recombinant Human Albumin in Europe.